Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Study uncovers source of genetic variation influencing childhood brain tumors

Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.

May 23, 2025

Vol.51 No.20

Clinical

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Diane Reidy-Lagunes joined Duke University School of Medicine’s Department of Medicine as chief of the Division of Medical Oncology, effective April 1.

May 02, 2025

Vol.51 No.17

Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

YOU MAY BE INTERESTED IN

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Study uncovers source of genetic variation influencing childhood brain tumors

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Renew today!

Subscriber content

Never miss an issue!

Login